Novilora® for Medical Professionals
A Science-Informed Nutritional Approach to Peripheral Nerve Support
Novilora® is the U.S. registered product name for OnLife®, an orally administered nutritional supplement developed in Italy and formulated with a patented, standardized combination of specific fatty acids and palmitoylethanolamide (PEA).
The formulation has been evaluated in clinical research involving adults with chemotherapy-induced peripheral neuropathy (CIPN) following paclitaxel- or oxaliplatin-based treatment. This Medical Professional Center provides an overview of the formulation, its proposed nutritional and physiological rationale, the available clinical evidence, its European development, and options for making Novilora® available directly to patients.
The Clinical Challenge of Chemotherapy-Induced Peripheral Neuropathy
Chemotherapy-induced peripheral neuropathy is a clinically significant and potentially persistent complication associated with several neurotoxic antineoplastic agents, including taxanes and platinum compounds.
CIPN most commonly manifests as a predominantly sensory, length-dependent neuropathy. Patients may report paresthesia, dysesthesia, numbness, burning discomfort, altered temperature sensitivity, impaired vibratory perception, and symptoms affecting balance, fine motor function, sleep, mobility, and activities of daily living. Motor and autonomic manifestations may also occur.
CIPN can persist after completion of chemotherapy and may materially affect function, quality of life, and survivorship. The formulation behind Novilora® was developed to provide targeted nutritional support for peripheral nerve structure and function in this clinical context.
A Patented Fatty Acid and PEA Formulation
Novilora® is based on the OnLife® formulation, which incorporates a patented, standardized group of fatty acids together with palmitoylethanolamide (PEA).
The formulation includes physiologically relevant lipids selected for their roles in cellular membrane composition, myelin integrity, lipid and energy metabolism, inflammatory balance, and intercellular signaling. PEA is an endogenous fatty acid amide that has been studied for its role in neuroinflammatory signaling and tissue homeostasis.
The formulation also contains magnesium pidolate and lycopene. Together, these components are intended to address specific nutritional requirements associated with peripheral nerve health.
Provides nutritional components relevant to peripheral nerve-cell membrane composition.
Supports the lipid substrates involved in myelin structure.
Includes lipids studied for their role in cellular energy metabolism.
PEA has been studied for its role in neuroinflammatory signaling and tissue homeostasis.
Provides nutritional components involved in intercellular signaling in peripheral nerves.
Contains lycopene, a carotenoid studied for its role in oxidative balance.
Published Clinical Evaluation
The OnLife® formulation was evaluated in the prospective, multicenter STEFANO observational study involving adults with persistent CIPN after completing adjuvant chemotherapy.
The analysis included 146 patients:
- 75 patients with breast cancer previously treated with a paclitaxel-based regimen
- 71 patients with colon cancer previously treated with an oxaliplatin-based regimen
Participants received OnLife® for three months. Peripheral sensory neuropathy and peripheral motor neuropathy were assessed before and after the evaluation period. Patient-reported CIPN symptoms and quality-of-life measures were also evaluated.
Investigator-assessed peripheral sensory neuropathy improved in 31.1% of patients and peripheral motor neuropathy improved in 37.5%.
Investigator-assessed peripheral sensory neuropathy improved in 16.9% of patients and peripheral motor neuropathy improved in 20.0%.
Patient-reported reductions in CIPN symptoms were also observed, with more pronounced findings in the paclitaxel-treated cohort. The investigators concluded that the observed findings supported further evaluation of the formulation in patients with CIPN.
The STEFANO study was prospective, multicenter, and observational. It was not a randomized, blinded, placebo-controlled clinical trial. Its findings should therefore be interpreted within the limitations of an uncontrolled observational design and should not be presented as definitive proof of efficacy.
Developed in Italy
The formulation behind Novilora® was developed by Again Life Italia, an Italian research and development company with a focus on patented nutritional formulations and the physiological processes associated with inflammation and neuroinflammation.
OnLife® was developed as a targeted nutritional formulation incorporating the proprietary F.A.G.® fatty acid complex. Novilora® now brings this established European formulation to the United States under its registered U.S. product name.
[INSERT FULL NAME AND CREDENTIALS OF CREATOR]
[INSERT VERIFIED PROFESSIONAL TITLE AND ROLE AT AGAIN LIFE ITALIA]
[INSERT APPROVED BIOGRAPHY, INCLUDING EDUCATION, SCIENTIFIC EXPERIENCE, RELEVANT PATENTS, PUBLICATIONS, AND ROLE IN DEVELOPING THE F.A.G.® FORMULATION]
[NAME AND CREDENTIALS] led or contributed to the development of the patented fatty acid formulation underlying OnLife® and Novilora®, with a research focus on the nutritional and physiological requirements of patients experiencing treatment-associated peripheral nerve dysfunction.
This profile will not be published until the creator's approved biography and photograph have been provided.
An International Research Perspective
This section will describe the creator's documented relationship with a Stanford-affiliated researcher, laboratory, program, or institution. No Stanford name, logo, seal, faculty affiliation, research partnership, endorsement, or collaboration claim will be published until Novilora provides documentation and exact approved wording.
- [INSERT VERIFIED NAME OF STANFORD SCHOOL, DEPARTMENT, LABORATORY, PROGRAM, FACULTY MEMBER, OR RESEARCH GROUP]
- [INSERT THE EXACT NATURE OF THE RELATIONSHIP — FORMAL RESEARCH COLLABORATION, ADVISORY RELATIONSHIP, VISITING APPOINTMENT, LICENSING RELATIONSHIP, OR JOINT PROJECT]
- [INSERT VERIFIED DATES, RESEARCH OBJECTIVES, AND OUTCOMES]
- [INSERT LINK TO AN OFFICIAL STANFORD PAGE, PUBLICATION, AGREEMENT, OR OTHER PRIMARY SOURCE]
European Development and Clinical Experience
Before its introduction in the United States as Novilora®, the OnLife® formulation was made available in European markets, including Germany and Switzerland.
The STEFANO observational study was sponsored by Swiss Medical Food AG, and its results were published in the peer-reviewed journal Oncology Research and Treatment. Study findings were also presented in connection with the 2020 German Cancer Congress in Berlin.
OnLife® has subsequently been distributed through established European channels serving patients and healthcare professionals. This history provides commercial and clinical-experience context for the U.S. introduction of Novilora®.
Specific figures on years of availability, packages distributed, participating physicians or pharmacies, and post-market or pharmacovigilance data will be added once documented by Novilora.
Provide Novilora® Directly to Your Patients
Novilora® offers a professional purchasing program for qualified medical practices, oncology and survivorship programs, integrative medicine practices, rehabilitation programs, pharmacies, and other approved healthcare organizations.
The program allows participating practices to maintain Novilora® inventory and make it conveniently available to appropriate patients as part of a clinician-supervised nutritional-support plan.
- Convenient access for patients through a trusted clinical setting
- U.S.-based product availability and fulfillment
- Professional product and formulation information
- Access to published clinical research
- Educational resources for clinicians and patients
- Volume-based professional pricing
- Support from the Novilora professional-services team
Professional purchasing is available only to verified healthcare practices, licensed healthcare professionals, pharmacies, and other approved healthcare organizations. Additional terms, minimums, shipping charges, resale requirements, and applicable taxes may apply. Program terms are being finalized and professional checkout will be activated once policies are confirmed.
Request a Professional Account
Considerations for Clinical Practice
Novilora® is a nutritional supplement and not a substitute for medical evaluation, diagnostic assessment, or individualized management of peripheral neuropathy.
Before recommending a nutritional supplement, clinicians should consider the patient's diagnosis, current and previous antineoplastic therapy, symptom onset and distribution, concomitant medications and supplements, allergies, dietary requirements, comorbidities, and other potential causes of peripheral neuropathy.
Patients experiencing new, progressive, severe, asymmetric, or otherwise atypical neurologic symptoms should receive appropriate medical evaluation.
Complete ingredient list, Supplement Facts, allergen information, and suggested-use details will be linked from this page once finalized.
Frequently Asked Questions for Clinicians
Is Novilora® a pharmaceutical product?+
No. Novilora® is a nutritional supplement and does not require a prescription. It is not FDA approved as a drug and is not intended to diagnose, treat, cure, or prevent disease.
What is the relationship between Novilora® and OnLife®?+
Novilora® is the registered U.S. product name for the formulation known in Europe as OnLife®. The formulation was developed in Italy and has been commercially available through European distribution channels.
What clinical evidence is available?+
The principal published evidence includes the prospective, multicenter STEFANO observational study of 146 adults with CIPN following paclitaxel- or oxaliplatin-based chemotherapy. The study reported changes in investigator-assessed sensory and motor neuropathy and patient-reported outcomes after three months. Because the study was observational and uncontrolled, the results should not be interpreted as evidence from a randomized, placebo-controlled trial.
Can Novilora® be used during active chemotherapy?+
The published STEFANO population received OnLife® after completion of the qualifying adjuvant chemotherapy regimens. Decisions concerning use during active treatment should be individualized by the treating clinician after reviewing the complete formulation, the patient's medical status, and concurrent therapy. The published study does not establish safety or effectiveness during active chemotherapy.
How can my practice provide Novilora® directly to patients?+
Qualified healthcare practices and organizations may apply for a professional purchasing account. Approved accounts can purchase Novilora® at the listed professional prices and maintain inventory for appropriate patient access, subject to the program's final terms.
Is professional educational material available?+
Yes. The Medical Professional Center will provide links to the published research, a clinician study summary, ingredient information, suggested-use information, and patient educational resources as those materials become available.